

# VASCADE<sup>®</sup> MVP

VASCULAR CLOSURE FOR EP PROCEDURES

**Early Ambulation**  
**Simple**  
**Proven**




Designed for EP.  
Proven by EPs.

**CARDIVA**  
MEDICAL, INC.

[www.cardivamedical.com](http://www.cardivamedical.com)

# Evolution of AF Ablation Workflow



# Early Ambulation

## A New Era

### Introducing VASCADE® MVP VASCULAR CLOSURE FOR EP<sup>1</sup> PROCEDURES

VASCADE MVP eliminates the need for manual compression and reduces time to ambulation by **64%**.<sup>2</sup>

Get patients up and moving hours earlier, with significantly less discomfort.<sup>3</sup>



# Simple

## Designed for EP Procedures

Dedicated to mid-bore  
(6–12F I.D.) multiple access  
venous closure<sup>4</sup>

### Simple and easy to use

- *Single operator*
- *No sutures or material left in the vessel*

### Extravascular design

- *No permanent or intraluminal implants*



### Bioabsorbable and thrombogenic collagen plug


- *Expands to fill tissue tract*

# Proven

## Proven by EPs

VASCADE MVP was evaluated in the AMBULATE pivotal trial. AMBULATE was a multicenter, randomized clinical trial with 204 patients randomized 1:1 to VASCADE MVP or manual compression.


### Manual Compression



### VASCADE MVP




### Opioid Use



**Number of Patients Receiving Opioids Post-Procedure<sup>3</sup>**


Manual Comp = 37 pts  
VASCADE MVP = 15 pts

### Patient Satisfaction with Duration of Bedrest



**Comparison of Bedrest for Patients with a Previous Cardiac Ablation Procedure<sup>3</sup>**

Manual Comp = 5.6 vs.  
VASCADE MVP = 7.9 mean<sup>5</sup>



**All Patients<sup>3</sup>**

Manual Comp = 5.1 vs.  
VASCADE MVP = 8.3 mean<sup>5</sup>

# Ordering Information

PRODUCT	CATALOG NUMBER	DESCRIPTION	QUANTITY
VASCADE MVP Venous Vascular Closure System (VVCS)	800-612C-10U	6–12 French (Inner Diameter)	1 box (10 devices per box)

The VASCADE MVP Venous Vascular Closure System (VVCS) Model 800-612C is indicated for the percutaneous closure of femoral venous access sites while reducing time to ambulation, total post-procedure time, time to hemostasis and time to discharge eligibility in patients who have undergone catheter-based procedures utilizing 6–12F inner diameter procedural sheaths, with single or multiple access sites in one or both limbs.

1. Electrophysiology (EP)
2. Percentage difference in median time to ambulation as reported in the IFU.
3. As demonstrated in the AMBULATE pivotal trial.
4. IFU and/or SSED for Vascade MVP.
5. On a scale of 0–10, with 0 being the worst and 10 being the best.

**CONTRAINDICATIONS:** The VASCADE MVP VVCS should not be used in patients with a known allergy to bovine derivatives.

**Before use, physicians should review all risk information, which can be found in the “Instructions for Use.”**

Founded in July 2002, CARDIVA Medical Inc. is a privately held medical device company that is focused on developing and commercializing innovative vascular closure technologies designed to help the body heal itself.



P: 866.602.6099 F: 866.602.1795  
customerservice@cardivamedical.com  
www.CardivaMedical.com

2018© Cardiva Medical, Inc.

VASCADE MVP is a registered trademark of Cardiva Medical, Inc.

Lit 4344 Rev A